Lead Product(s): Sinapultide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Ladenburg Thalmann & Co
Deal Size: $20.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 22, 2020
Windtree intends to use the net proceeds from this offering to advance the study of KL4 surfactant to treat COVID-19 related lung injury; istaroxime acute heart failure phase 2b start-up activities;clinical development of AEROSURF;pre-clinical studies of SERCA2a activators.